VAERS Explorer
Back to explore

Report #2848432

Received Jul 4, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Male
Age
0.3 yrs
State
MI
Recovered
Unknown
Vaccinated
Jul 1, 2025
Onset
Jul 1, 2025
Days to onset
0
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
DTAPIPVHIBDTAP + IPV + HIB (PENTACEL)SANOFI PASTEURUNKUK038AAOT / LL

Symptoms (2)

Expired product administeredNo adverse event

Symptom narrative

administration of an expired product with no reported adverse event; Initial information received on 01-Jul-2025 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 3 months old male patient who was administered with an expired dose of diphtheria/tetanus/5 hybrid AC pertussis/IPV(VERO)/HIB(PRP/T) vaccine [Pentacel (VERO)] with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On 01-Jul-2025, the patient received 0.5 ml of an expired diphtheria/tetanus/5 hybrid AC pertussis/IPV(VERO)/HIB(PRP/T) vaccine Powder and suspension for suspension for injection with standard strength (expiry date- 30-Jun-2025 and lot UK038AA) once via intramuscular route in the left thigh for Immunization with no reported adverse event (expired product administered) (latency- same day). Reportedly, reporter would like to know the possible adverse reactions and if there was a need to revaccinate. Action taken was not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.